Co-Diagnostics Inc. (0A50)
LSE 
NASDAQ Primary LSE Summary
0A50 Chart
Is Co-Diagnostics National Security's Next Diagnostic Pick?
A structural shift is underway in the biodefense landscape. The declaration of a Public Health Emergency of International Concern (PHEIC) by the World Health Organization on May 17, 2026, for the Bundibugyo virus Ebola outbreak should be seen by investors as more than a headline, because it is a fundamental catalyst.
Co-Diagnostics, Inc. (CODX) Q1 2026 Earnings Call Transcript
Co-Diagnostics, Inc. (CODX) Q1 2026 Earnings Call Transcript
Co-Diagnostics, Inc. (CODX) Q4 2025 Earnings Call Transcript
Co-Diagnostics, Inc. (CODX) Q4 2025 Earnings Call Transcript
Co-Diagnostics Inc. (0A50) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Co-Diagnostics Inc. ever had a stock split?
Co-Diagnostics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dwight H. Egan CEO | LSE Exchange | US1897632048 ISIN |
| US Country | 132 Employees | - Last Dividend | 2 Jan 2026 Last Split | 12 Jul 2017 IPO Date |
Overview
Co-Diagnostics, Inc. is a pioneering molecular diagnostics company that engages in the development, manufacturing, and sale of reagents used for tests that function via the detection and/or analysis of nucleic acid molecules. Operating both in the United States and internationally, the company has carved a niche for itself in the field of diagnostic tests, focusing on a wide array of infectious diseases. Established in 2013 and based in Salt Lake City, Utah, Co-Diagnostics, Inc. has expanded its footprint globally, offering an extensive array of diagnostic solutions catering to several health concerns and industries. The company's commitment to innovation is evident in its offering of advanced molecular tools for the detection of infectious diseases, agricultural applications, and more.
Products and Services
Co-Diagnostics, Inc. offers an extensive range of products and services aimed at providing diagnostic solutions and advancing the field of molecular diagnostics. These include:
- Polymerase Chain Reaction (PCR) Diagnostic Tests: The company specializes in PCR diagnostic tests for a number of infectious diseases such as COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. These tests play a crucial role in the early detection and management of infectious diseases globally.
- Multiplexed Tests: Co-Diagnostics provides three multiplexed tests designed for testing mosquitos to identify various diseases they carry. This innovative approach aids in controlling and preventing the spread of mosquito-borne diseases.
- Molecular Tools: A wide range of molecular tools for the detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications are part of their offerings. These tools facilitate the accurate and timely diagnosis of diseases, contributing to better patient outcomes and agricultural productivity.
- Genetic Trait Identification Tests: The company offers tests that identify genetic traits in plant and animal genomes. This technology supports advancements in agriculture and livestock breeding by enabling the selection of desirable traits.
- Portable PCR Device: Co-Diagnostics has developed a portable PCR device designed to bring PCR diagnostic capabilities to patients in point-of-care and at-home settings. This innovation enhances access to diagnostic tests, making it convenient for users to receive timely health assessments.
- Diagnostic Equipment Sales: In addition to its proprietary diagnostic tests and devices, Co-Diagnostics intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. This expansion allows the company to offer comprehensive diagnostic solutions to its clients.
